Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

anthera pharmaceuticals inc - ANTH

ANTH

Close Chg Chg %
0.00 0.00 9,900.00%

Closed Market

0.00

0.00 (9,900.00%)

Volume: 2.49K

Last Updated:

Dec 30, 2025, 12:17 PM EDT

Trade Now

Company Overview: anthera pharmaceuticals inc - ANTH

ANTH Key Data

Open

$0.00

 Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.00

 Market Cap

$0.00

Shares Outstanding

26.18M

 Public Float

26.13M

Beta

-488.24

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.70

Yield

N/A

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

14.40K

  

ANTH Performance

1 Week
 
 9,900.00%
 
1 Month
 
 0.00%
 
3 Months
 
 9,900.00%
 
1 Year
 
 0.00%
 
5 Years
 
 N/A
 

ANTH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Anthera Pharmaceuticals Inc - ANTH

Collapse All in section
All values USD millions. 2014 2015 2016 2017 5-year trend
Sales/Revenue
- - 3.19M 145.00K
-
Sales Growth
- - -95.45% -100.00%
-
Cost of Goods Sold (COGS) incl D&A
- - 344.00K 281.00K
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
344.00K 285.00K 266.00K 281.00K
Depreciation
344.00K 285.00K 266.00K 281.00K
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -2.55%
-
Gross Income
- - (344.00K) (281.00K)
-
Gross Income Growth
- - - +2.55%
-
Gross Profit Margin
- - - -
-
2014 2015 2016 2017 5-year trend
SG&A Expense
28.11M 40.78M 57.32M 36.25M
Research & Development
21.84M 33.50M 46.51M 28.59M
Other SG&A
6.28M 7.28M 10.80M 7.66M
SGA Growth
+0.79% +45.05% +40.55% -36.75%
Other Operating Expense
- - - -
-
Unusual Expense
- - (1.74M) (9.64M)
-
EBIT after Unusual Expense
(28.46M) (37.88M) (55.69M) (26.89M)
Non Operating Income/Expense
(96.00K) 2.66M 171.00K 15.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 1.05M
-
Interest Expense Growth
- - -59.64% -100.00%
-
Gross Interest Expense
- - - 1.05M
-
Interest Capitalized
- - - -
-
Pretax Income
(29.60M) (35.22M) (55.52M) (26.87M)
Pretax Income Growth
+4.07% -18.97% -57.65% +51.60%
Pretax Margin
- - -1,105.81% -38,291.72%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - (28.93M)
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 28.93M
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(29.60M) (35.22M) (55.52M) (26.87M)
Minority Interest Expense
- - - -
-
Net Income
(29.60M) (35.22M) (55.52M) (26.87M)
Net Income Growth
+4.07% -18.97% -57.65% +51.60%
Net Margin Growth
- - -1,105.81% -38,291.72%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(29.60M) (35.22M) (55.52M) (26.87M)
Preferred Dividends
- - 10.91M 2.50M
-
Net Income Available to Common
(29.60M) (35.22M) (66.44M) (29.38M)
EPS (Basic)
-10.88 -7.92 -12.88 -2.86
EPS (Basic) Growth
+19.53% +27.21% -62.63% +77.80%
Basic Shares Outstanding
2.72M 4.45M 5.16M 10.28M
EPS (Diluted)
-10.88 -7.92 -12.88 -2.86
EPS (Diluted) Growth
+19.53% +27.21% -62.63% +77.80%
Diluted Shares Outstanding
2.72M 4.45M 5.16M 10.28M
EBITDA
(28.11M) (37.60M) (57.17M) (36.25M)
EBITDA Growth
-0.79% -33.72% -52.07% +36.59%
EBITDA Margin
- - -1,180.41% -39,428.97%
-

Anthera Pharmaceuticals Inc in the News